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Our aims were to genotype Chlamydia trachomatis strains present in urogenital samples and to investigate the occurrence of the
Swedish new variant of C. trachomatis in Finland. We genotyped 160 C. trachomatis positive samples with ompA real-time PCR
andanalyzed495samplesforthe new variant.The three mostprevalentgenotypes were E (40%),F (28%),and G(13%).Onlytwo
specimens containing bacteria with the variant plasmid were detected. It seems that in Finland the percentage of infections due to
genotypes F and G has slightly increased during the last 20 years. Genotypes E and G appear to be more common, and genotypes
J/Ja and I/Ia appear to be less common in Europe than in the USA. Although the genotype E was the most common genotype
amongC. trachomatis strains, the new variant was rarely found in Finland.
1.Introduction
Chlamydia trachomatis, an obligate intracellular bacterium,
is worldwide a common cause of sexually transmitted
infections. Even asymptomatic infections can lead to serious
sequelae such as infertility and ectopic pregnancy. The
infections are very prevalent among adolescents, and rein-
fections are common [1]. Young people with C. trachomatis
constitute an important target group for public health
interventions. Since 1995, the number of C. trachomatis
infections has been oﬃcially notiﬁed in Finland, and the
numberofnotiﬁcations hasbeen increasing. Lately,therehas
been around 14 000 notiﬁed cases annually (250 cases/100
000 inhabitants) [2]. In Finland, C. trachomatis infections
are diagnosed mainly with sensitive and speciﬁc nucleic
acid ampliﬁcation tests (NAATs), but these tests do not
diﬀerentiate between genotypes.
The seroimmunological analysis of C. trachomatis major
outer membrane protein (MOMP) ﬁrst leads to the identi-
ﬁcation of ≥15 diﬀerent serovars, and sequence diﬀerences
in the ompA gene, especially in the areas coding the variable
domains of MOMP, later conﬁrmed this discrimination [3,
4]. C. trachomatis types A–C cause trachoma, types D–K
cause urogenital infections, and types L1–L3 cause lym-
phogranuloma venereum (LGV). C. trachomatis has also a
cryptic plasmid which is commonlyusedas a target sequence
in diagnostic NAATs. In 2006, there was an unexpected fall
in C. trachomatis cases in Sweden, which was caused by
the appearance of a new variant of C. trachomatis (nvCT)
with a 377 base pair deletion in the cryptic plasmid [5].
At the same time, the proportion of urogenital samples
that tested positive by Cobas TaqMan CT Test, old version
(Roche), decreased slightly in Southern Finland (Dr. Jukka
Suni, HUSLAB; personal communication).
The purpose of this work was to set up a real-time PCR-
b a s e dm e t h o df o rg e n o t yp i n gC. trachomatis(typesD–Kand
L1–L3) in urogenital samples. Additionally, we wanted to set
up a method for detection of the Swedish nvCT and to study
the occurrence of this variant in Finland.2 Infectious Diseases in Obstetrics and Gynecology
2.Materialsand Methods
2.1. Clinical Samples and DNA Extraction. In 2008, 160
unselected C. trachomatis positive specimens from females
and males were collected for genotyping. The ﬁrst-void
urines (N = 82), cervical/vaginal swabs (N = 75), and
conjunctival swabs (N = 3) had been sent to HUSLAB,
Department of Virology for C. trachomatis nucleic acid
testing. HUSLAB, the diagnostic laboratory of the Helsinki
University Central Hospital serving the capital area, used
at that time both Aptima Combo 2 Assay (Gen-Probe)
and Cobas TaqMan CT Test (Roche). Of the 160 samples,
84 tested C. trachomatis positive with Gen-Probe and 76
with Roche test. Additionally, 38 C. trachomatis negative
clinical samples were included as negative controls. To
estimate the prevalence of the Swedish nvCT in Finland, 495
urogenital samples were studied. Of these samples, 469 were
C. trachomatis positive with Aptima Combo 2 Assay (Gen-
Probe) (N = 414) or Cobas TaqMan CT Test, new version
(Roche) (N = 55), and 26 were negative with Cobas TaqMan
CT Test, old version (Roche). As the prevalence of the nvCT
atthattimewasquitehighinSweden[6],weinitiallyplanned
tocollectspecimensthattestedC.trachomatisnegativebythe
old version of the Cobas TaqMan CT Test (Roche), which
fails to detect them. However, the test was soon replaced
by a new dual-target version by the manufacturer, and the
majority of our material consisted of C. trachomatis positive
specimens.
For genotyping, DNA was extracted from a specimen
volume of 400µL with MagNA Pure Compact instrument
(Roche) using MagNA Pure Compact Nucleic Acid Isolation
Kit I (Roche) with DNA Bacteria protocol and eluted in
50µL. For detection of the nvCT, DNA was extracted from
a specimen volume of 200µLw i t hM a g N AP u r eL C( R o c h e )
instrument using MagNA Pure LC DNA Isolation Kit I
(Roche) with DNAI Blood Cells High Performance protocol
and eluted in 100µL. The concentration of total DNA
was measured with a NanoDrop 1000 spectrophotometer
(Thermo Scientiﬁc). DNA extracted from the samples was
stored at −70◦C until analysis.
2.2. Real-Time PCR. Genotyping was performed according
to a method described previously by Jalal et al. [7]. The
method is based on the sequence variation of the ompA
gene, and it has two primer sets and elevengenotype-speciﬁc
TaqMan probes for types D–K and L1–L3. In this study,
we used the non-nested version of the method. As controls,
DNA extracted from C. trachomatis reference strains (types
A–K and L2) originally from ATCC (American Type Culture
Collection) propagated in McCoy cells (mouse ﬁbroblast
cells) [8]w a su s e d .
To screen for the Swedish nvCT, we used a method
developed by Catsburg et al. [9]. This method has primers
and a TaqMan probe ﬂanking the deletion sequence in
the cryptic plasmid of C. trachomatis. A clinical sample
containing the nvCT, kindly provided by Professor Bj¨ orn
Herrmann,Uppsala,Sweden,wasusedtoconstructapositive
control for the assay. The sequence ﬂanking the deletion
was ampliﬁed and cloned into a plasmid vector with Zero
BluntTOPOPCRCloningKit(Invitrogen LifeTechnologies)
according to the manufacturer’s instructions. Plasmids were
extracted with QIAprep Spin Miniprep Kit (QIAGEN), and
the DNA concentration was measured with a NanoDrop
1000 spectrophotometer (Thermo Scientiﬁc).
Real-time PCR analyses were performed with an ABI
7500 instrument and Sequence Detection Software version
1.3.1 (Applied Biosystems). The primers and probes used
in this study were purchased from Applied Biosystems,
Metabion International AG, or TAG Copenhagen A/S. The
PCR reactions were performed in a 25µL volume containing
250nM primers, 100nM probes, and either 12.5µLP l a t -
inum Quantitative PCR SuperMix-UDG (Invitrogen Life
Technologies) or 12.5µL TaqMan Universal Master Mix
(Applied Biosystems). Thermal cycling conditions were,
50◦C2m i n u t e s ,9 5 ◦C1 0m i n u t e sa n d4 0c y c l e so f9 5 ◦C
15 seconds and 60◦C 1 minute. Template volume was 2µL
or 5µL for genotyping and 2µLf r o mt w od i ﬀerent samples
pooled together for detection of the nvCT.
3.Results
Of the 160 C. trachomatis positive clinical samples analyzed,
144 (90%) could be genotyped. Ninety % of both ﬁrst-void
urines and swab samples sent for NAAT contained enough
chlamydial DNA for the ompA PCR. Sixteen samples (10%)
remained without a genotype with the non-nested version
o ft h eu s e dm e t h o dw h i c hw a sm o s tl i k e l yd u et ot h el o w
amount of chlamydial DNA present in the specimens. The
ompA genotype distribution of the strains is presented in
Tables 1 and 2. Genotypes E (N = 57, 40%), F (N = 41,
28%), and G (N = 19, 13%) were the most prevalent
in this study and comprised together over 80% of the C.
trachomatis ﬁndings. The 16 samples that remained negative
for genotypes D–K were analyzed for genotypes L1–L3. We
did not detect any genotypes L1–L3 in these urogenital
samples. All the 38 C. trachomatis negative clinical samples
tested also negative in genotyping PCR.
Among the 469 C. trachomatis positive clinical samples
screened for the Swedish nvCT, samples from two female
patients were found to contain a bacteria with the variant
plasmid (0.4%). One of the samples was ﬁrst-void urine and
the other a vaginal swab. Both of the nvCT were of genotype
E,ashasbeendescribedalsoinSwedenandelsewhere [6,21].
Both also harbored a cryptic plasmid with a deletion site in
the ORF1, and the sequence ﬂanking the deletion in both
strains was identical to that of the Swedish nvCT (conﬁrmed
bysequencing)[5].Theclinicalsamples containingthenvCT
were both initially tested by the Aptima Combo 2 Assay
(Gen-Probe) that is based on detection of the ribosomal
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Table 1: The ompA genotype distribution (%) of 144 clinical
C. trachomatis strains from this study (2008) compared with the
distribution of types in isolates from the same laboratory in 1996
(ompA PCR and restriction fragment length polymorphism,RFLP)











B2 2 N D
E 2 53 34 0
D 698
ED 25 ND ND
D/B ND 2 ND
t o t a l 5 84 64 8
F 1 02 22 8
G 4 13 13
K 825
t o t a l 2 23 74 6
C 0 ND ND
C/J ND 6 ND
C-group ND 8 ND
H 633
I6 N D 0
J/Ja 8 ND 2
total 20 17 5
ND: not determined.
C - g r o u p :g e n o t y p e sA ,C ,H ,I ,I a ,J ,K ,a n dL 3 .
sexual networks. It potentially also assists in understanding
the pathogenesis of these infections for example, whether
genotypes are associated with clinical phenotypes [22]o r
clearance of infection [20]o rd i ﬀerentiating between new,
repeated, and persistent infection [23, 24]. This information
is elementary in eﬀorts to monitor and prevent spread
of C. trachomatis infections. Typing of C. trachomatis has
traditionally been based on diﬀerences in MOMP or the
ompA gene coding it. Lately, also high-resolution genotyping
for C. trachomatis [24, 25] has been developed. These novel
methodscouldbeadvantageous especially when strains from
a geographically localized area or from a population where
certain ompA genotypes dominate are analyzed.
Of the unselected C. trachomatis positive specimens
sent to the diagnostic laboratory for NAAT, 90% contained
enough DNA to allow genotyping. Based on an ompA PCR,
the most prevalent C. trachomatis genotypes in Finland were
E, F, and G comprising approximately 80% of the strains
that could be typed. The proportion of types F and G seems
to have increased whereas the proportion of types D and E
seems to have remained rather stable, when set against the
typing results from 1987 (monoclonal antibodies) [10]a n d
1996 (ompA PCR and restriction fragment length polymor-
phism, RFLP) [11]. Although the diﬀerent methods used
in these studies and the relatively small numbers of strains
typed could partly explain the observed diﬀerences, these
might be true changes. Indeed, also in Seattle, Washington,
with a method based on monoclonal antibodies, a similar
change was reported: the proportion of infections due to
serovars F and G increased in 1988–1996 [17].
When the type distribution in Europe (Finland, Sweden
before the appearance of the nvCT [12, 13], the Netherlands
[14, 15], and Portugal [16]) and in the USA [17–20]w a s
evaluated, the proportion of types E and G tended to
be slightly lower in the USA than in Europe, while the
proportion of types J/Ja and I/Ia seemed somewhat higher in
the USA than in Europe. Again, the typing methods varied
(see Table 2). However, when the European data is compared
to that obtained with ompA sequencing in the USA, the
aforementioned observations still remain [19, 20].
Although the typing method used also detects geno-
types L1–L3, we did not detect any L types among the
urogenital specimens tested. Classic LGV infections caused
by genotypes L1–L3 have been uncommon in the Western
Countries, including Finland. However, lately outbreaks of
proctitis caused by type L2 among HIV-positive MSM have
been reported in many European countries [26].
Certain C. trachomatis sero-/genotypes have been linked
to certain clinical features for example abdominal pain,
pelvic inﬂammatory disease, and pregnancy complications,
b u ta l s ot oa s y m p t o m a t i ci n f e c t i o n s[ 18, 22, 27–29]. As the
associations remain weak at best, it is not likely that typing
ompA or ompA encoded protein MOMP of the urogenital
strains will reveal clues to their pathogenicity. Classiﬁcation
relying on other, yet unidentiﬁed virulence attributes might
betterreﬂectassociations ofcertainC.trachomatissubgroups
with disease severity, persistence, or asymptomaticity [30].
Also host factors are likely to modulate the outcome of the
infection.
T h ee m e r g e n c eo ft h eS w e d i s hn v C Th a sc l e a r l yp o i n t e d
out the importance of epidemiologic surveillance and atten-
tive evaluation of results obtained using diagnostic test kits.
Diagnostictestsshouldtargetsequencesthatareconservative
and essential for the bacterium. As the cryptic plasmid is not
absolutely essential for survival of C. trachomatis,m u t a t i o n s
in the plasmid genes can even lead to a selection advantage
for C. trachomatis [31]. In this study, we were able to ﬁnd
only two clinical samples with the Swedish nvCT, which
was expected: only few cases outside Sweden have been
reported and most often the cases were linked to Sweden
[32].Unfortunately, we couldnot obtain information on our
patients whether they had contacts to Sweden because they
were both lost from follow-up. Although the decrease in the
positivity rate by the Cobas TaqMan CT Test, old version
(Roche), in a major Finnish diagnostic laboratory could not
be explained by the appearance of nvCT, this exercise has
considerably improved our ability to detect novel variants.
5.Conclusions
In this study, we showed that the most prevalent genotype
in Finland was E (40%). However, the Swedish variant was
rare in Finland despite our close proximity to Sweden and
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